Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer

Hideya Onishi, Takashi Morisaki, Eishi Baba, Hirotaka Kuga, Hideo Kuroki, Kotaro Matsumoto, Masao Tanaka, Mitsuo Katano

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)


Dendritic cells (DCs) are antigen-presenting cells specialized for the induction of the primary T-cell response. Tumor immunotherapy using DCs loaded with tumor antigens is under way for patients with several types of advanced malignancies. In this study, DC-like cells (Mo-DCs) were generated from peripheral blood monocytes with granulocyte-macrophage colony-stimulating factor and interleukin-4. The antigen-presenting abilities, including capture of apoptotic tumor cells, IL-12 secretion, expression of antigen-presentation-related molecules (HLA-ABC, HLA-DR, and CD80), and mixed leukocyte reaction, of Mo-DCs from 37 patients with advanced cancer (pMo-DCs) were compared to those of 20 healthy volunteers (hMo-DCs). Seven days after the initial culture, no significant difference was found in either the number or the size of Mo-DC-forming colonies between the two groups. However, most of the antigen-presenting abilities of pMo-DCs were weaker than those of hMo-DCs on day 7. On day 14, both number and size of colonies were significantly decreased in pMo-DCs but not in hMo-DCs. Interestingly, the antigen-presenting abilities of the remaining pMo-DCs gradually strengthened with time and by day 14 no significant difference was observed between pMo-DCs and hMo-DCs. These results indicate that pMo-DCs contain dysfunctional and short-lived Mo-DC subsets.

Original languageEnglish
Pages (from-to)286-295
Number of pages10
JournalClinical Immunology
Issue number3
Publication statusPublished - Dec 1 2002

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer'. Together they form a unique fingerprint.

Cite this